Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells
Telomir Pharmaceuticals (NASDAQ:TELO) has announced breakthrough preclinical results for its drug Telomir-1 in prostate cancer treatment. The study revealed that Telomir-1 reduced tumor size by approximately 50% in a prostate cancer animal model using aggressive human prostate cancer cells.
Key findings show that Telomir-1 actively suppresses cancer growth and protects against chemotherapy-induced toxicity when combined with Paclitaxel. While Paclitaxel alone showed severe toxicity with one-third mortality in test animals, no deaths occurred when combined with low-dose Telomir-1.
The study also addressed concerns about telomere-elongating drugs potentially promoting cancer, demonstrating instead that Telomir-1 exhibits anti-cancer effects while benefiting healthy cells. The company is advancing Telomir-1 across multiple indications, including age-related macular degeneration and Wilson's disease, with plans to submit an Investigational New Drug application by year-end.
Telomir Pharmaceuticals (NASDAQ:TELO) ha annunciato risultati preclinici innovativi per il suo farmaco Telomir-1 nel trattamento del cancro alla prostata. Lo studio ha rivelato che Telomir-1 ha ridotto la dimensione del tumore di circa 50% in un modello animale di cancro alla prostata utilizzando cellule aggressive di cancro alla prostata umano.
I risultati chiave mostrano che Telomir-1 sopprime attivamente la crescita del cancro e protegge contro la tossicità indotta dalla chemioterapia quando combinato con Paclitaxel. Mentre il Paclitaxel da solo ha mostrato tossicità severa con un terzo di mortalità negli animali da test, non si sono verificati decessi quando combinato con Telomir-1 a bassa dose.
Lo studio ha anche affrontato preoccupazioni riguardo ai farmaci che allungano i telomeri che potrebbero promuovere il cancro, dimostrando invece che Telomir-1 presenta effetti anti-cancro pur beneficiando le cellule sane. L'azienda sta portando avanti Telomir-1 in diverse indicazioni, inclusa la degenerazione maculare legata all'età e la malattia di Wilson, con piani per presentare una domanda di Nuovo Farmaco Investigativo entro la fine dell'anno.
Telomir Pharmaceuticals (NASDAQ:TELO) ha anunciado resultados preclínicos innovadores para su medicamento Telomir-1 en el tratamiento del cáncer de próstata. El estudio reveló que Telomir-1 redujo el tamaño del tumor en aproximadamente 50% en un modelo animal de cáncer de próstata utilizando células agresivas de cáncer de próstata humano.
Los hallazgos clave muestran que Telomir-1 suprime activamente el crecimiento del cáncer y protege contra la toxicidad inducida por quimioterapia cuando se combina con Paclitaxel. Mientras que el Paclitaxel solo mostró una toxicidad severa con un tercio de mortalidad en los animales de prueba, no se produjeron muertes cuando se combinó con Telomir-1 a baja dosis.
El estudio también abordó preocupaciones sobre los medicamentos que alargan los telómeros que podrían promover el cáncer, demostrando en cambio que Telomir-1 exhibe efectos anticancerígenos mientras beneficia a las células sanas. La empresa está avanzando con Telomir-1 en múltiples indicaciones, incluida la degeneración macular relacionada con la edad y la enfermedad de Wilson, con planes de presentar una solicitud de Nuevo Medicamento en Investigación para fin de año.
텔로미르 제약 (NASDAQ:TELO)은 전립선암 치료를 위한 약물 텔로미르-1의 혁신적인 전임상 결과를 발표했습니다. 연구 결과, 텔로미르-1은 공격적인 인간 전립선암 세포를 사용한 전립선암 동물 모델에서 종양 크기를 약 50% 줄였습니다.
주요 발견은 텔로미르-1이 암 성장 억제를 적극적으로 수행하고, 파클리탁셀과 함께 사용 시 화학요법 유도 독성으로부터 보호함을 보여줍니다. 파클리탁셀 단독 사용 시 실험 동물에서 3분의 1이 사망하는 심각한 독성이 나타났지만, 저용량의 텔로미르-1과 결합했을 때는 사망이 발생하지 않았습니다.
이 연구는 텔로미어 연장 약물이 암을 촉진할 수 있다는 우려를 다루었으며, 대신 텔로미르-1이 건강한 세포에 이익을 주면서 항암 효과를 나타낸다는 것을 입증했습니다. 이 회사는 텔로미르-1을 노화 관련 황반 변성과 윌슨병을 포함한 여러 적응증에서 진행 중이며, 연말까지 임상시험용 신약 신청서를 제출할 계획입니다.
Telomir Pharmaceuticals (NASDAQ:TELO) a annoncé des résultats précliniques révolutionnaires pour son médicament Telomir-1 dans le traitement du cancer de la prostate. L'étude a révélé que Telomir-1 réduisait la taille de la tumeur d'environ 50% dans un modèle animal de cancer de la prostate utilisant des cellules agressives de cancer de la prostate humain.
Les résultats clés montrent que Telomir-1 supprime activement la croissance du cancer et protège contre la toxicité induite par la chimiothérapie lorsqu'il est combiné avec le Paclitaxel. Alors que le Paclitaxel seul a montré une toxicité sévère avec un tiers de mortalité chez les animaux de test, aucune mort n'est survenue lorsqu'il était combiné avec Telomir-1 à faible dose.
L'étude a également abordé les préoccupations concernant les médicaments allongeant les télomères qui pourraient favoriser le cancer, démontrant plutôt que Telomir-1 présente des effets anticancéreux tout en bénéficiant aux cellules saines. L'entreprise fait progresser Telomir-1 dans plusieurs indications, y compris la dégénérescence maculaire liée à l'âge et la maladie de Wilson, avec des plans pour soumettre une demande de médicament expérimental d'ici la fin de l'année.
Telomir Pharmaceuticals (NASDAQ:TELO) hat bahnbrechende präklinische Ergebnisse für sein Medikament Telomir-1 zur Behandlung von Prostatakrebs bekannt gegeben. Die Studie ergab, dass Telomir-1 die Tumorgröße in einem tierexperimentellen Modell für Prostatakrebs mit aggressiven menschlichen Prostatakrebszellen um etwa 50% reduzierte.
Wichtige Ergebnisse zeigen, dass Telomir-1 aktiv das Wachstum von Krebs hemmt und vor durch Chemotherapie induzierter Toxizität schützt, wenn es mit Paclitaxel kombiniert wird. Während Paclitaxel allein schwere Toxizität mit einer Sterblichkeit von einem Drittel bei den Testtieren zeigte, traten keine Todesfälle auf, wenn es mit einer Niedrigdosis von Telomir-1 kombiniert wurde.
Die Studie ging auch auf Bedenken ein, dass telomerverlängernde Medikamente möglicherweise Krebs fördern könnten, und zeigte stattdessen, dass Telomir-1 krebshemmende Wirkungen hat und gleichzeitig gesunde Zellen begünstigt. Das Unternehmen entwickelt Telomir-1 für mehrere Indikationen weiter, darunter altersbedingte Makuladegeneration und Wilson-Krankheit, mit dem Plan, bis Ende des Jahres einen Antrag auf ein neues Prüfpräparat einzureichen.
- Demonstrated 50% tumor size reduction in prostate cancer animal models
- Proved effectiveness in preventing chemotherapy-induced toxicity and mortality
- Showed dual benefit: cancer suppression while protecting healthy cells
- Advanced development across multiple medical indications
- Clear pathway to IND submission by year-end
- Still in preclinical stage, requiring extensive clinical trials before potential approval
- Results to animal models, human efficacy yet to be proven
Insights
Telomir Pharmaceuticals' preclinical findings for Telomir-1 represent a significant scientific breakthrough with dual therapeutic potential. The compound demonstrated approximately 50% tumor reduction in prostate cancer animal models while simultaneously neutralizing chemotherapy toxicity when combined with Paclitaxel.
What makes these results particularly compelling is that Telomir-1 challenges a fundamental concern in longevity science. Rather than promoting cancer growth (a theoretical risk for telomere-elongating compounds), it actively suppresses tumor development. This dual mechanism - extending cellular health while inhibiting cancer - creates a distinctive therapeutic profile with potential applications across multiple disease areas.
The chemoprotective properties are especially noteworthy from a clinical perspective. In the study, Paclitaxel alone caused severe toxicity with one-third mortality in test animals, while adding Telomir-1 eliminated mortality completely. This suggests Telomir-1 could address one of chemotherapy's greatest limitations - dose-limiting toxicity - potentially enabling more effective cancer treatment regimens with reduced side effects.
The company's targeted IND submission by year-end indicates an accelerated development timeline. While these preclinical results are promising, investors should recognize that the transition from animal models to human trials represents a critical validation point where many drug candidates encounter challenges. Success would position Telomir-1 as a potential platform technology with applications across oncology and age-related diseases.
The preclinical data for Telomir-1 highlights a potentially paradigm-shifting approach to cancer treatment through its dual mechanisms. Most notably, the compound demonstrated 50% tumor reduction at both low and high doses in aggressive prostate cancer models, suggesting significant anti-tumor activity independent of dosage intensity.
What distinguishes Telomir-1 from conventional cancer therapies is its innovative mechanism targeting oxidative stress through metal ion regulation. This approach directly addresses the paradox that has chemotherapy effectiveness - the balance between cancer cell destruction and healthy tissue preservation. By potentially neutralizing the reactive oxygen species generated during chemotherapy without compromising efficacy, Telomir-1 represents a mechanistically novel chemoprotectant.
The findings directly contradict the theoretical concern that telomere-elongating compounds might accelerate cancer progression. Instead, Telomir-1 demonstrates selective benefits: promoting healthy cell maintenance while actively suppressing malignant growth. This selective activity profile suggests potential applications as both a standalone treatment and as an adjuvant to existing therapies.
From a clinical development perspective, Telomir's approach of targeting multiple indications (oncology, AMD, Wilson's disease) provides several potential regulatory pathways and diversifies development risk. While these animal model results are encouraging, the critical next steps will include human pharmacokinetics, dosing optimization, and safety profiling in Phase 1 trials. The targeted IND submission timeline suggests we could see initial human data within approximately 18-24 months.
Telomir-1 Inhibits Tumor Growth, Suppresses Cancer Progression, and Neutralizes Chemotherapy Toxicity
MIAMI, FLORIDA / ACCESS Newswire / March 19, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir"), a leader in age-reversal science, today announced groundbreaking preclinical findings demonstrating that Telomir-1 reduces tumor size by approximately
Key findings include:
Telomir-1 alone at both low and high doses reduced tumor growth by approximately
50% .Contrary to concerns that telomere-elongating drugs may promote cancer, Telomir-1 demonstrated the opposite effect-actively suppressing tumor development, while selectively benefiting healthy cells.
In the group treated with Paclitaxel alone, severe toxicity was observed, leading to significant weight loss and mortality of one-third of the animals. However, when low-dose Telomir-1 was added to Paclitaxel, no mortality occurred.
Telomir-1 as a Chemotherapy Protector: The Potential Role of Oxidative Stress
Paclitaxel and other chemotherapy agents induce toxicity largely through oxidative stress, which results in excessive damage to healthy cells and contributes to severe side effects. It is known that metal ions such as iron and copper play significant roles in amplifying the reactive oxygen species (ROS)-mediated effects of Paclitaxel, primarily through their involvement in redox chemistry and the Fenton reaction. We believe that Telomir-1's ability to reverse oxidative stress, through its metal ion-regulatory activities may be responsible for eliminating chemotherapy-induced toxicity in this study.
"We are on the verge of something truly transformational," said Erez Aminov, CEO of Telomir. "Pioneering an entirely new approach to fighting disease, Telomir-1 addresses toxicity at its root cause. The ability to protect healthy cells while enhancing treatment effectiveness has the potential to redefine modern medicine. This is more than an incremental improvement-Telomir-1 represents a foundational platform that could reshape the standard of care across multiple fields. The science is compelling, the need is urgent, and the opportunity ahead is extraordinary."
Addressing the Long-Standing Concern About Telomere Elongation and Cancer Risk
A long-standing concern in longevity science is that drugs that elongate telomeres may promote cancer, as cancer cells rely on telomere size maintenance for immortality. Telomir-1 has already been shown in multiple human cell lines to successfully elongate telomeres, raising this theoretical risk. However, this latest study demonstrates that Telomir-1 does not promote cancer growth but instead has anti-cancer effects, directly inhibiting tumor growth and reducing tumor size in a prostate cancer model.
This groundbreaking finding suggests that Telomir-1 may selectively benefit healthy cells while suppressing malignant growth, challenging the assumption that telomere-elongating drugs inherently increase cancer risk. Instead, Telomir-1 emerges as a promising candidate for both oncology and longevity applications.
"There has long been a debate about whether telomere elongation could fuel cancer growth, but our findings provide compelling evidence that Telomir-1 does more than just lengthen telomeres-it actively suppresses tumor development," said Dr. Angel, Chief Scientific Advisor at Telomir. "These results not only confirm in-vitro observations in aggressive, androgen-independent human prostate cancer cells but also represent a game-changing discovery in animal models. We are seeing a drug that extends cellular health while simultaneously protecting against the very toxicity that often limits treatment success."
Advancing Telomir-1 Toward Clinical Development
Telomir Pharmaceuticals is actively advancing Telomir-1 across multiple indications. In addition to oncology, ongoing studies are evaluating Telomir-1 in age-related diseases such as age-related macular degeneration (AMD) and Wilson's disease, a rare orphan disorder affecting copper metabolism.
The company is prioritizing the fastest pathway to clinical trials and aims to submit its Investigational New Drug (IND) application by year-end.
"We are working aggressively to submit our IND by year-end," said Aminov. "As we continue optimizing our drug manufacturing processes and advancing pre-IND animal safety studies, our team is laser-focused on bringing Telomir-1 one step closer to clinical trials. Every milestone we achieve reinforces our belief that Telomir-1 has the potential to become a breakthrough therapy for multiple life-altering diseases."
About Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) is a pre-clinical stage pharmaceutical company seeking to lead development in several areas, including age-reversal science. Telomir is focused on the development of Telomir-1, a novel small molecule metal ion regulator designed to lengthen the DNA's protective telomere caps, which are crucial in the aging process. Telomir's goal is to explore the potential of Telomir-1, starting with ongoing research in animals and then in humans.
Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents humans and pet animals with an increased chance of contracting a number of degenerative and age-related diseases. Telomir's goal is to develop and gain regulatory approval for Telomir-1, proposed to be dosed orally, with the broader aim of promoting longevity and enhancing overall quality of life.
Telomir-1 is in preclinical development and has not yet been tested in humans. There is no assurance that Telomir-1 will proceed through development or will ultimately receive FDA approval for marketing.
Cautionary Note Regarding Forward-Looking Statements
This press release, statements of Telomir Pharmaceuticals' management or advisors related thereto, and the statements contained in the news story linked in this release contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.
Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications and safety of Telomir-1. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact Information
Helga Moya
info@telomirpharma.com
(786) 396-6723
SOURCE: Telomir Pharmaceuticals, Inc
View the original press release on ACCESS Newswire
FAQ
What were the key results of Telomir-1's prostate cancer study in 2025?
How does Telomir-1 (TELO) interact with chemotherapy drug Paclitaxel?
What is the timeline for Telomir Pharmaceuticals (TELO) IND application?
Does Telomir-1 promote cancer growth through telomere elongation?
What other conditions is Telomir-1 (TELO) being developed for?
